Alexion Pharmaceuticals, Inc.
Quick facts
| Founded | 1992 |
|---|
Marketed products
- Ultomiris · Other
Phase 3 pipeline
- ALXN1850 · Nephrology / Immunology
ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases. - ALXN2060 · Immunology / Hematology
ALXN2060 is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage. - C5 Inhibitor · Immunology
A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation. - CAEL-101 · Rare Disease / Amyloidosis
CAEL-101 is a transthyretin (TTR) stabilizer that binds to and stabilizes the transthyretin protein, preventing its misfolding and amyloid fibril formation. - pexelizumab in conjunction with CABG · Cardiovascular
Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.
Phase 2 pipeline
- ACH-0144471 · Autoimmune diseases
ACH-0144471 is a monoclonal antibody targeting the CD40 receptor. - ACH-126,443
- ALXN1920
- ALXN2030 · Genetics and Rare Diseases
ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy. - ALXN2420
- Bis-Choline Tetrathiomolybdate · Neurology
Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain. - hLB-001
- Retrospective Case Only
Phase 1 pipeline
- [14C]-ALXN2050
- [14C]-Danicopan
Inhibits complement factor D, blocking the alternative pathway of the complement system. - ACH-0143102
- ACH-0145228
- ACH-0145228: Immediate Release
- ACH-0145228: Powder-in-capsule
- ALXN1007
- ALXN1210 · Rare Disease
Complement inhibitor - ALXN1210 IV · Rare Disease
ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade. - ALXN1210 SC
Inhibits complement protein C5, preventing the formation of the membrane attack complex and reducing complement-mediated cell destruction. - ALXN1720
- ALXN1720 IV
- ALXN1720 SC
- ALXN1820 IV
- ALXN1820 SC
- ALXN1840 Enteric-coated Tablet
- ALXN1840 Non-coated Capsule
- ALXN1910
- ALXN2040
- ALXN2050 MR Prototype Mini-Tablet
- ALXN2050 MR Prototype Tablet
- ALXN2080
- ALXN2230
- ALXN2350
- AZP-3601
- Danicopan - LFC
- Danicopan Modified Release Prototype 1
Inhibits complement factor D, blocking the alternative pathway of the complement system. - Danicopan Modified Release Prototype 2
Danicopan is a factor D inhibitor that blocks the alternative complement pathway, preventing excessive complement activation. - Danicopan Modified Release Prototype 3
Danicopan is a selective oral inhibitor of complement factor D, blocking the alternative pathway of the complement system. - Danicopan: Powder-In-Capsule 1
Danicopan inhibits complement factor D, blocking the alternative pathway of the complement system. - Danicopan: Powder-In-Capsule 2
- Danicopan - Softgel
- Danicopan - Tablet
- Gefurulimab AI
- Gefurulimab PFS-SD
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Alexion Pharmaceuticals, Inc.
What are Alexion Pharmaceuticals, Inc.'s marketed drugs?
Top marketed products include Ultomiris.
What is Alexion Pharmaceuticals, Inc.'s pipeline?
Alexion Pharmaceuticals, Inc. has 5 drugs in Phase 3, 8 in Phase 2, 35 in Phase 1. Late-stage candidates include ALXN1850, ALXN2060, C5 Inhibitor, CAEL-101.
When was Alexion Pharmaceuticals, Inc. founded?
Alexion Pharmaceuticals, Inc. was founded in 1992.
How many employees does Alexion Pharmaceuticals, Inc. have?
Alexion Pharmaceuticals, Inc. has approximately 3,837 employees.
Related
- Ultomiris · Other
- Sector hub: All tracked pharma companies